基于数据挖掘的国家专利中药复方治疗糖尿病足用药规律分析

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (1766 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze medication rules of national patents on Chinese medicine compounds in the intervention for diabetic foot (DF) based on data mining method, and to provide references for the optimization of clinical prescriptions and medications. Methods In the Chinese patent announcement interface of China National Intellectual Property Administration website, “‘diabetic foot’ and ‘traditional Chinese medicine’”, “‘diabetic foot’ and ‘Chinese herb’”, and “‘gangrene of consumptive thirst’ and ‘Chinese herb’” were used as search terms, and the search period was from the establishment of the database to August 30, 2021, in order to search the patents of Chinese herbs treating DF. Frequency statistics were performed by Excel 2019, and association rules and systematic cluster analysis were performed by using SPSS Modeler 18.0, SPSS 26.0, and Cytoscape 3.7.2 softwares, respectively, in order to mine the core Chinese herbs combinations. Results A total of 56 patents and 56 traditional Chinese medicine compound combinations were included; there were 270 kinds of Chinese herbs, and the top three with high frequency were Astragali Radix, Angelicae Sinensis Radix, and Salviae Miltiorrhizae Radix Et Rhizoma; the four nature of drugs were mainly pungent and salty, the five flavors were mainly warm and cold, the spleen and liver meridians were in the majority; the top ten supporting of Chinese medicine association rules were Astragali Radix-Salviae Miltiorrhizae Radix Et Rhizoma, Astragali Radix-Chuanxiong Rhizoma, Astragali Radix-Carthami Flos, etc.; the top 30 Chinese herbs were divided into seven groups by systematic cluster analysis; the new prescriptions included Astragali Radix, Salviae Miltiorrhizae Radix Et Rhizoma, Angelicae Sinensis Radix, and Paeoniae Radix Rubra. Conclusion In the treatment of DF, Astragali Radix combined with traditional Chinese medicine for promoting blood circulation and removing blood stasis is mostly used, and different core drug combinations are selected according to the different double clip syndrome.

Key words： Diabetic foot Traditional Chinese medicine compound Data mining Medication rule National patent

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Xueyun1 CHEN Chunxiao1 ZHAO Ling2

Cite this article:

HUANG Xueyun1 CHEN Chunxiao1 ZHAO Ling2. Analysis of medication rules of national patents on Chinese medicine compounds in treating diabetic foot based on data mining[J]. 中国医药导报, 2022, 19(13): 10-14.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I13/10

[1] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志，2021，13（4）：315-409.
[2] 王富军.中国糖尿病足防治指南（2019版）解读[J].河北医科大学学报，2019，40（11）：1241-1245，1250.
[3] Lazzarini PA，Pacella RE，Armstrong DG，et al. Diabetes-related lower-extremity complications are a leading cause of the global burden of disability [J]. Diabet Med，2018，35（9）：1297-1299.
[4] 刘欣，王云飞.中医药治疗糖尿病足溃疡的研究进展[J].海南医学院学报，2021，27（16）：1277-1280.
[5] 国家药典委员会.中华人民共和国药典[M].一部.北京：中国医药科技出版社，2020.
[6] 国家中医药管理局中华本草编委会.中华本草[M].上海：上海科学技术出版社，1999.
[7] Shannon P，Markiel A，Ozier O，et al. Cytoscape：a software environment for integrated models of biomolecular interaction networks Genome Research [J]. Genome Res，2003，13（11）：2498-2504.
[8] 曹烨民.“脱疽”的历史演变及现代意义[J].血管与腔内血管外科杂志，2019，5（6）：540-544.
[9] 巢元方.诸病源候论[M].北京：中国医药科技出版社，2011.
[10] 王维德.外科证治全生集[M].北京：人民卫生出版社，1956.
[11] 卫燕文，柳国斌.糖尿病足的中医证型分析[J].辽宁中医杂志，2011，38（1）：27-29.
[12] 钱秋海.活血化瘀防治糖尿病及并发症机制探讨[J].山东中医杂志，2002（3）：131-133.
[13] 邓莉娟，杨光耀，鞠上.从“糖毒损络”角度初探糖尿病足发病机制与特点[J].疑难病杂志，2021，20（11）：1157-1160.
[14] 曾丽红，李霖芝，岳仁宋.岳仁宋从“糖毒-玄府-络脉”理论辨治糖尿病足经验[J].成都中医药大学学报，2021， 44（3）：40-43.
[15] 何元旭，何志军，刘涛，等.糖尿病足发病机制研究进展[J].河南中医，2020，40（10）：1614-1617.
[16] 刁元元，李玉梅，李晓文，等.黄芪抗糖尿病并发症的研究进展[J].中国比较医学杂志，2021，31（4）：123-128.
[17] 张臻，阙华发.黄芪多糖与糖尿病创面愈合相关机制研究进展[J].中医学报，2020，35（6）：1202-1206.
[18] 邓来明，肖正华，陈定宇.黄芪多糖对糖尿病足溃疡成纤维细胞AGEs及RAGEmRNA表达的影响[J].今日药学，2014，24（5）：313-315.
[19] 谢玲，杨凌红，李晓惠．当归药理作用研究进展[J].中医药研究，2000，16（6）：56-58．
[20] 袁子文，钟立甲，纪鹏，等.当归干预血瘀证大鼠血浆代谢组学研究[J].天然产物研究与开发，2018，30（4）：559-567.
[21] 王文越，刘珊，吕琴，等.黄芪-当归药对益气活血药理作用研究进展[J].中国实验方剂学杂志，2021，27（6）：207-216.
[22] 王梦梦，吉兰芳，崔树娜.丹参功效的物质基础研究进展[J].中医学报，2019，34（5）：944-949.
[23] 刘晓可，刘晓瑞，黄彬洋，等.从脾论治糖尿病下肢大血管病变[J].河南中医，2017，37（8）：1392-1394.
[24] 刘姝璇.从肝论治糖尿病研究进展[J].河南中医，2021， 41（12）：1939-1944.
[25] 段艳，张万明，刘天骥.疮家圣药话黄芪[J].国医论坛，1997（3）：44.
[26] 赵金超，杜玉青，李创，等.活血通脉法干预糖尿病下肢血管病介入术后支架内再狭窄的疗效观察[J].北京中医药，2020，39（6）：526-530.